| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
No specific biological target. HO-PEG-CH2COOH (MW 35000) is a polymer, not a drug, and does not interact with receptors or enzymes in a pharmacological manner. Its purpose is as a building block for PEGylation of proteins, peptides, nanoparticles, or surfaces. PEGylation improves pharmacokinetics, reduces immunogenicity, and enhances stability of therapeutic proteins. The carboxylic acid group allows conjugation to amine groups via amide bond formation (after activation with EDC/NHS). The hydroxyl group can be used for further derivatization. The high molecular weight (35 kDa) imparts long circulation half-life when conjugated to drugs. This product is a research tool, not a therapeutic agent.
|
|---|---|
| ln Vitro |
Not applicable (polymer reagent). HO-PEG-CH2COOH (MW 35000) is not used in in vitro activity assays (e.g., enzyme inhibition, cell proliferation). It is a linker for conjugation. In vitro, the polymer itself is inert and non-cytotoxic at typical concentrations (0.1-10 mg/mL). It does not affect cell viability, signaling, or metabolism. However, when conjugated to a drug, the PEGylation may alter the drug's activity, solubility, and stability. The compound can be used to PEGylate therapeutic proteins to reduce immunogenicity and extend half-life. No direct activity data are available.
|
| ln Vivo |
Not applicable. HO-PEG-CH2COOH (MW 35000) is not administered as a drug. When conjugated to a therapeutic protein, the conjugate may be administered in vivo. For example, PEG-interferon or PEG-filgrastim are approved drugs. The PEG linker itself is inert and non-immunogenic. In animal studies, high molecular weight PEGs (35 kDa) have a long plasma half-life (several days) due to reduced renal clearance. They are generally well-tolerated but can cause vacuolation in renal tubules at very high doses. The compound is for research use as a conjugation reagent, not for direct in vivo administration.
|
| Enzyme Assay |
For quality control and characterization, a non-cellular assay is not typical. However, the PEG can be characterized by gel permeation chromatography (GPC) to confirm molecular weight and polydispersity. The carboxylic acid content can be determined by titration with NaOH or by using a colorimetric assay (e.g., Toluidine Blue O). Activation to NHS ester can be verified by reaction with a primary amine (e.g., glycine) and detection of the amide bond by FTIR or by HPLC. For conjugation to a protein, a typical protocol involves activating the PEG-COOH with EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and NHS (N-hydroxysuccinimide) in MES buffer (pH 5.5) for 30 min, then adding the protein in PBS (pH 7.4). After reaction, purify the PEGylated protein by size exclusion chromatography. The PEGylation efficiency can be assessed by SDS-PAGE.
|
| Cell Assay |
Not applicable. HO-PEG-CH2COOH (MW 35000) is not used directly in cell-based assays. It can be used to PEGylate cell surfaces or to prepare PEGylated liposomes. For PEGylation of living cells, the PEG-COOH can be activated and reacted with cell surface amines, but this is not common. For a typical conjugation procedure to a protein drug candidate, the protein is dissolved in PBS (pH 7.4). Separately, dissolve HO-PEG-CH2COOH (35 kDa) in water or DMSO. Add EDC (5-10 molar excess) and NHS (5-10 fold) to the PEG solution in MES buffer (pH 5.5), activate for 15-30 min. Then add the activated PEG to the protein solution (1:1 to 10:1 molar ratio of PEG:protein). Incubate for 2-4 h at room temperature. Quench with glycine or lysine. Purify by dialysis or size exclusion chromatography. Analyze by SDS-PAGE or MALDI-TOF for conjugation efficiency. This is a laboratory reagent; no cell-based activity is measured.
|
| Animal Protocol |
Not applicable. The compound is not administered to animals as a drug. However, when conjugated to a protein, the conjugate may be dosed. For example, in a PK study, a PEGylated protein (e.g., PEG-interferon) is administered to mice intravenously or subcutaneously. The PEG linker itself is not the active moiety. As a reagent, HO-PEG-CH2COOH (35k) can be used to create PEGylated nanoparticles for drug delivery. For in vivo distribution studies, the PEG chain can be labeled with a fluorophore or radionuclide. However, the product as supplied is non-labeled. There are no standard in vivo protocols for the unmodified polymer alone.
|
| ADME/Pharmacokinetics |
For a high molecular weight PEG (35 kDa), the pharmacokinetics are very different from small molecules. When administered intravenously to rodents, PEG of this size has a plasma half-life of 1-3 days because it is above the renal clearance threshold (≈30-50 kDa). It is not significantly metabolized; excretion is via renal filtration for smaller fragments, but large PEG is slowly cleared by the reticuloendothelial system. The volume of distribution is limited to the vascular space and extracellular fluid. The polymer is non-toxic and non-immunogenic. However, repeated high doses may cause vacuolation in renal proximal tubules (a known effect of high molecular weight PEGs). For PEGylation of therapeutic proteins, the PEG linker contributes to the extended half-life of the conjugate. For research use, the compound is a standard linker.
|
| Toxicity/Toxicokinetics |
High molecular weight PEGs (e.g., 35 kDa) are considered safe and have been used in FDA-approved PEGylated drugs (e.g., Pegasys, Neulasta). In preclinical studies, repeated intravenous administration of PEG 35 kDa at doses >100 mg/kg may cause cytoplasmic vacuolation in renal tubular epithelial cells, which is reversible. No genotoxicity or carcinogenicity is associated with PEG itself. The acute toxicity is very low (LD50 >10 g/kg in rodents). The compound is not intended for human use as a drug; it is a reagent. Standard laboratory safety precautions (gloves, lab coat) should be used. Avoid inhalation of dust.
|
| References | |
| Additional Infomation |
HO-PEG-CH2COOH (MW 35000) is a heterobifunctional PEG derivative with -OH and -COOH termini. It is used for PEGylation to improve the pharmacological properties of proteins, peptides, and small-molecule drugs. PEGylation reduces renal clearance, increases solubility, and reduces immunogenicity. The carboxylic acid group allows easy conjugation via amide bond formation after activation with EDC/NHS. The hydroxyl group can be further functionalized (e.g., tosylation, mesylation, or conversion to amine). This product is for research use only and is not an FDA-approved drug. It is supplied as a white powder and stored at 2-8degC or -20degC. Common applications include creating PEG-drug conjugates, PEGylated liposomes, and surface coatings for biomaterials.
|
| Molecular Weight |
35000.00
|
|---|---|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~12.5 mg/mL (~0.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.0286 mL | 0.1429 mL | 0.2857 mL | |
| 5 mM | 0.0057 mL | 0.0286 mL | 0.0571 mL | |
| 10 mM | 0.0029 mL | 0.0143 mL | 0.0286 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
